2024 年转移性前列腺癌的系统治疗。

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-08-09 DOI:10.1016/j.euf.2024.07.013

Marco Gizzi, Emmanuel Seront, Bertrand Tombal, Julien Van Damme

{"title":"2024 年转移性前列腺癌的系统治疗。","authors":"Marco Gizzi, Emmanuel Seront, Bertrand Tombal, Julien Van Damme","doi":"10.1016/j.euf.2024.07.013","DOIUrl":null,"url":null,"abstract":"Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systemic Treatments for Metastatic Prostate Cancer in 2024.\",\"authors\":\"Marco Gizzi, Emmanuel Seront, Bertrand Tombal, Julien Van Damme\",\"doi\":\"10.1016/j.euf.2024.07.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.\",\"PeriodicalId\":4,\"journal\":{\"name\":\"ACS Applied Energy Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Energy Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2024.07.013\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2024.07.013","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

摘要

晚期转移性前列腺癌是一种异质性疾病，雄激素剥夺疗法联合雄激素受体通路抑制剂（ARPI）是其主要治疗手段。在使用 ARPI 后，可依次使用所有可用的疗法。然而，患者的选择是关键。有必要确定临床或分子预测因素，以帮助选择系统治疗顺序。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Systemic Treatments for Metastatic Prostate Cancer in 2024.

Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.